Autoimmune gastritis Medical Services in China

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by the progressive destruction of gastric parietal cells and intrinsic factor–producing chief cells in the gastric corpus and fundus. This leads to achlorhydria (absent or severely reduced gastric acid secretion), hypergastrinemia, and impaired vitamin B12 absorption—ultimately resulting in pernicious anemia if untreated. Pathogenesis centers on loss of immune tolerance: autoreactive CD4+ T lymphocytes infiltrate the gastric mucosa, triggering antibody production against parietal cell H+/K+ ATPase (the proton pump) and intrinsic factor. These autoantibodies—particularly anti–H+/K+ ATPase antibodies—are highly specific (>90%) for AIG and serve as key diagnostic biomarkers. Complement activation and cytokine-driven mucosal atrophy further perpetuate glandular loss, metaplasia (often intestinal), and increased risk of gastric neuroendocrine tumors (type I carcinoids) and gastric adenocarcinoma. Epidemiologically, AIG affects approximately 0.5–2% of the general population, with prevalence rising sharply with age—reaching 2–5% in adults over 60 years. It is significantly more common in women (F:M ≈ 3:1) and strongly associated with other autoimmune conditions, including Hashimoto’s thyroiditis (30–50% co-occurrence), type 1 diabetes mellitus (5–10%), vitiligo, and Addison’s disease. Genetic susceptibility involves HLA-DRB1*03:01 and HLA-DQB1*02:01 alleles. Environmental triggers remain poorly defined but may include molecular mimicry following viral or bacterial infections (e.g., Helicobacter pylori—though AIG is typically H. pylori-negative, prior infection may modulate immune responses). Risk factors include female sex, age >50 years, personal or family history of autoimmunity, and certain genetic polymorphisms in immune-regulatory genes (e.g., CTLA-4, PTPN22). Clinically, AIG is often insidious and asymptomatic in early stages; when symptoms emerge, they are frequently nonspecific—fatigue, pallor, dyspnea on exertion (due to B12-deficiency anemia), glossitis, paresthesias, or mild epigastric discomfort. Importantly, patients rarely report classic dyspepsia or reflux, distinguishing AIG from functional dyspepsia or H. pylori gastritis. Quality of life impact is substantial but underrecognized: chronic fatigue and cognitive fog from B12 deficiency impair work performance and daily functioning; neurological complications (subacute combined degeneration) may become irreversible without timely intervention; psychological burden includes anxiety about cancer risk and lifelong dependency on injectable or high-dose oral B12 replacement. Long-term surveillance via endoscopy with targeted biopsies is recommended every 3–5 years in patients with extensive atrophy or intestinal metaplasia to detect dysplasia or early neoplasia. Patient education, multidisciplinary care (gastroenterology, hematology, endocrinology), and proactive monitoring are essential to mitigate morbidity and preserve quality of life.

Autoimmune gastritis (AIG) is a chronic, immune-mediated inflammatory disorder characterized by T-lymphocyte infiltration of the gastric corpus and fundus, leading to progressive atrophy of parietal and chief cells, achlorhydria, and intrinsic factor deficiency. This results in impaired vitamin B12 absorption and subsequent pernicious anemia, as well as elevated serum gastrin levels due to loss of acid feedback inhibition. AIG is strongly associated with other autoimmune conditions—including Hashimoto’s thyroiditis, type 1 diabetes mellitus, and vitiligo—and carries an increased risk of gastric neuroendocrine tumors (type 1 gastric carcinoids) and gastric adenocarcinoma, albeit at low absolute incidence. Management focuses on lifelong surveillance, nutritional repletion, and complication prevention rather than disease modification, as no therapy currently halts or reverses the underlying autoimmune destruction.

Conservative treatment forms the cornerstone of AIG management and emphasizes regular monitoring and lifestyle adaptation. Patients require lifelong endoscopic surveillance—typically every 3–5 years—to detect dysplasia, early neoplasia, or type 1 gastric carcinoids, especially in those with persistent hypergastrinemia (>1000 pg/mL), extensive atrophy, or intestinal metaplasia. Upper gastrointestinal endoscopy with high-definition white-light imaging and targeted biopsies (per Sydney System protocol: antrum, incisura, corpus, and fundus) is mandatory for baseline staging and longitudinal assessment. Serum biomarkers—including fasting gastrin, pepsinogen I, pepsinogen II, and the pepsinogen I/II ratio—are monitored annually to track gastric atrophy progression. Nutritional counseling is integral: patients must avoid proton pump inhibitors (PPIs) unless absolutely indicated (e.g., concomitant GERD), as exogenous acid suppression exacerbates hypergastrinemia and may theoretically promote enterochromaffin-like (ECL) cell hyperplasia. Dietary modifications include small, frequent meals rich in bioavailable iron (heme iron from lean meats), folate (leafy greens, legumes), and calcium/vitamin D to mitigate osteoporosis risk secondary to chronic achlorhydria and potential malabsorption.

Pharmacotherapy in AIG is entirely supportive and symptom- or deficiency-driven. Vitamin B12 replacement is non-negotiable for all patients with documented deficiency (serum B12 <200 pg/mL) or functional deficiency (elevated methylmalonic acid or homocysteine). Intramuscular cyanocobalamin (1000 µg monthly after initial loading doses) remains first-line; however, high-dose oral B12 (1000–2000 µg daily) is equally effective in most cases and preferred for long-term adherence, given its safety and lack of need for injections. Iron supplementation (ferrous sulfate 325 mg 1–3× daily, with vitamin C to enhance absorption) is initiated for iron-deficiency anemia, often requiring 3–6 months of therapy followed by maintenance dosing if ongoing losses or malabsorption persist. Folate supplementation (1–5 mg daily) may be added in cases of megaloblastic anemia unresponsive to B12 alone. Notably, immunosuppressive agents—including corticosteroids, azathioprine, or biologics—have no proven efficacy in AIG and are contraindicated due to lack of benefit and significant infection/malignancy risks. PPIs should be used sparingly and only under gastroenterologist supervision, with strict documentation of indication and periodic reassessment.

Surgical intervention has no role in the primary management of AIG. Gastrectomy or antrectomy is neither indicated nor beneficial for controlling autoimmunity or preventing complications. However, surgery becomes necessary in rare, advanced scenarios: endoscopically unresectable type 1 gastric carcinoids (>1 cm, multifocal, or with invasion beyond the lamina propria) may require endoscopic mucosal resection (EMR) or, less commonly, laparoscopic wedge resection or distal gastrectomy. Similarly, high-grade dysplasia or early gastric adenocarcinoma mandates oncologic resection per Japanese Gastric Cancer Association (JGCA) or NCCN guidelines. These procedures are performed exclusively by specialized upper GI surgeons in high-volume centers and are not curative for AIG itself but address discrete malignant complications.

Treatment advantages in China stem from integrated, multidisciplinary infrastructure and policy-driven accessibility. First, China’s national gastric cancer screening program—implemented in high-risk regions since 2012—provides standardized, subsidized endoscopy and histopathology for individuals with chronic atrophic gastritis, enabling earlier AIG detection and risk stratification. Second, Chinese tertiary hospitals (e.g., Peking Union Medical College Hospital, Zhongshan Hospital Fudan University) host dedicated Autoimmune GI Clinics where gastroenterologists, endocrinologists, hematologists, and nutritionists collaborate on longitudinal care, including rapid turnaround for serum gastrin/pepsinogen assays (<48 hours) and digital pathology review. Third, China manufactures high-quality generic formulations of cyanocobalamin, ferrous fumarate, and folate at <10% the cost of branded equivalents in Western markets, ensuring affordability for lifelong supplementation. Fourth, AI-assisted endoscopic systems (e.g., EndoBRAIN, developed by Olympus and Shanghai Jiao Tong University) improve detection sensitivity for subtle ECL hyperplasia and microcarcinoids during surveillance, reducing interobserver variability. Finally, China’s National Health Commission mandates electronic health record integration across provinces, facilitating seamless tracking of B12 levels, endoscopy intervals, and biopsy results—critical for preventing gaps in chronic disease management.

Recovery and long-term prognosis hinge on strict adherence to surveillance and supplementation—not ‘cure,’ as AIG is irreversible. Patients should undergo annual complete blood count, serum B12, ferritin, folate, and vitamin D testing; repeat upper endoscopy per risk-stratified intervals (every 3 years for severe atrophy/hypergastrinemia; every 5 years for mild-moderate disease). Smoking cessation and alcohol abstinence are strongly advised, as both accelerate gastric mucosal damage. Patients must be counseled that fatigue, glossitis, or neuropathy signal possible B12 inadequacy—even with supplementation—and warrant immediate evaluation. Pregnancy requires intensified monitoring: B12 doses may increase to 1000 µg twice weekly, and fetal neural tube defect risk necessitates concurrent high-dose folate (4–5 mg/day) preconception through the first trimester. With consistent care, life expectancy is normal; however, 10–15% develop gastric carcinoids over 20 years, and 1–3% progress to adenocarcinoma—underscoring that vigilance, not passivity, defines successful recovery. Ultimately, AIG management epitomizes preventive gastroenterology: proactive, personalized, and perpetually vigilant.